PISCATAWAY, N.J., [February 10, 2026] : Kashiv
BioSciences, LLC (“Kashiv”) a vertically integrated biopharmaceutical company,
today announced that it has entered into an exclusive licensing and supply
agreement with Intas Pharmaceuticals Ltd (“Intas”), a leading multinational
pharmaceutical company. The complex peptide product will be commercialized by
Intas in India and its subsidiary, Accord Healthcare Ltd (“Accord”), in Europe
and the UK.
The agreement covers pan-European, UK, and
India markets. Under the terms of the agreement, Kashiv will be responsible for
the regulatory registration, manufacturing and supply of the product, while
Accord will manage the commercialization and distribution across the regions.
“Our partnership with Intas, leveraging its
strong pan-European presence through Accord, enables Kashiv to expand our
commercial reach across key European, UK, and Indian markets and strengthen our
overall portfolio in the regions,” said Dr. Sandeep Athalye, Global CEO of
Kashiv BioSciences. “This collaboration reflects our shared commitment to
improving patient outcomes and aligns with our mission to make high-quality,
affordable therapies more accessible for patients worldwide.”
“We are pleased to partner with Kashiv
BioSciences to expand access to high-quality therapies across Europe, the UK
and India. By combining our capabilities, we aim to strengthen our presence and
better serve the unmet needs of patients and healthcare professionals,” said
Mr. Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals.
About Kashiv BioSciences
Kashiv BioSciences, LLC
is a vertically integrated biopharmaceutical company with numerous commercial
and advanced clinical-stage assets and is among the few U.S.-based companies to
both manufacture and receive marketing authorization for multiple biosimilars.
Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together
“Kashiv BioSciences”) operate together with robust infrastructure and highly
skilled teams that provide global R&D, clinical, manufacturing, regulatory,
and IP capabilities. We believe our people, partners, and shared purpose fuel
our work to advance patient care and access to important medicines. For more
information, visit www.kashivbiosciences.com and follow us on LinkedIn.
About Intas
Pharmaceuticals
Intas Pharmaceuticals
Ltd. is a leading vertically integrated pharmaceutical company headquartered in
Ahmedabad, India, with group revenues of USD 2.6 billion. Intas has end- to-end
capabilities across formulation development, manufacturing and marketing, including
API integration, and strong in-house biosimilar capabilities with more than 15
marketed products. The company operates in 85 countries and employs over 22,000
people. For more information, visit www.intaspharma.com.
About Accord
Healthcare:
Headquartered in the
United Kingdom, Accord Healthcare is one of the fastest-growing pharmaceutical
companies in Europe. It boasts one of the largest market footprints among
European generic and biosimilars companies, selling medicines in over 85
countries worldwide. This global reach allows Accord to provide essential,
affordable medicines to national health systems, assisting healthcare
professionals in improving patient lives worldwide. Accord is committed to being
agile and inventive, continually seeking to enhance products and improve
patient access.
Media Contacts –
For Kashiv BioSciences:
Dr. Paras Vasanani
Global Head – Business
Development, Portfolio & Strategy paras.vasanani@kashivbio.com
Heena Dhedhi
Head – Corporate
Communications heena.dhedhi@kashivbio.com
For Intas
Pharmaceuticals:
Suresh Keshwani
AVP – Business Development
suresh_keshwani@intaspharma.com